



[Home](#) / [Investors](#) / [Press Releases](#)

Insmmed to Present at the 34th Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Insmmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that company management will participate at the 34th Annual J.P. Morgan Healthcare Conference on January 11-14, 2016 in San Francisco. Will Lewis, president and chief executive officer of Insmmed, will deliver a corporate overview on Wednesday, January 13th at 9:00 AM PT.

Mr. Lewis' presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be archived for a period of 90 days following the live webcast.

About Insmmed

Insmmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal when left untreated. There are currently no products indicated for the treatment of NTM lung disease in the United States or European Union (EU). In the EU, the company has filed a marketing authorization application seeking approval of ARIKAYCE for use in patients with NTM lung disease. Insmmed's earlier-stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil that the company is developing for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. To complement its internal research, Insmmed actively seeks in-licensing opportunities for a broad range of rare diseases. For more information, visit www.insmed.com.

"Insmmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
